Allogene Therapeutics (ALLO) EBITDA (2018 - 2026)
Allogene Therapeutics (ALLO) posted EBITDA of -$46.1 million for Q1 2026, down 8.7% sequentially from -$42.4 million in Q4 2025, and up 29.3% YoY from -$35.6 million in Q1 2025.
Allogene Therapeutics (ALLO) EBITDA (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported EBITDA for 9 years, with the latest figure at -$46.1 million in Q1 2026.
- Quarterly EBITDA rose 29.3% year-over-year to -$46.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$190.2 million (up 29.26% YoY) and the FY2025 annual result came in at -$209.3 million, up 23.38% from the prior year.
- EBITDA declined to -$46.1 million in Q1 2026 per ALLO's latest filing, from -$42.4 million in the prior quarter.
- Over five years, EBITDA peaked at -$42.4 million in Q4 2025 and troughed at -$99.1 million in Q1 2023.
- A 5-year average of -$70.1 million and a median of -$71.4 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2025: EBITDA slumped 5747.04% in 2022, then soared 37.44% in 2025.
- Over 5 years, EBITDA stood at -$96.4 million in 2022, then climbed by 11.71% to -$85.1 million in 2023, then increased by 28.93% to -$60.5 million in 2024, then increased by 29.9% to -$42.4 million in 2025, then slipped by 8.7% to -$46.1 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$46.1 million, -$42.4 million, and -$44.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | -46.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -46.92 Mn |
| Mar 31, 2026 | -46.09 Mn |
| Dec 31, 2025 | -42.40 Mn |
| Sep 30, 2025 | -44.90 Mn |
| Jun 30, 2025 | -56.82 Mn |
| Mar 31, 2025 | -65.19 Mn |
| Dec 31, 2024 | -60.49 Mn |
| Sep 30, 2024 | -71.77 Mn |
| Jun 30, 2024 | -71.43 Mn |
| Mar 31, 2024 | -69.50 Mn |
| Dec 31, 2023 | -85.11 Mn |
| Sep 30, 2023 | -63.00 Mn |
| Jun 30, 2023 | -80.54 Mn |
| Mar 31, 2023 | -99.09 Mn |
| Dec 31, 2022 | -96.40 Mn |
| Sep 30, 2022 | -82.51 Mn |
| Jun 30, 2022 | -76.62 Mn |
| Mar 31, 2022 | -80.01 Mn |
| Dec 31, 2021 | 1.71 Mn |
| Sep 30, 2021 | -77.67 Mn |